Puzigaća Z, Prelević G M, Sretenović Z
Centre for Family Planning and Human Reproduction, Belgrade, Yugoslavia.
Gynecol Endocrinol. 1994 Mar;8(1):39-43. doi: 10.3109/09513599409028456.
Twenty-four women (mean age 42.0 +/- 2.4 years) with leiomyoma underwent treatment with a gonadotropin releasing hormone (GnRH) agonist (buserelin) for 6 months at a dose of 1200 micrograms daily intranasally for the first 2 months, followed by 900 micrograms daily for 4 months. The volume of the uterus and of individual leiomyomas were measured by echosonography before treatment, every 2 months during treatment, and every 2 months for 6 months after cessation of therapy (a total of 7 evaluations). A control group, comprising 14 women with untreated leiomyoma, underwent ultrasound scanning every 2 months for 6 months. A significant reduction in the volume of the uterus and leiomyomas was observed after the first 2 months of treatment in all but one patient. Leiomyomas showed a greater reduction in volume (54.6 +/- 2.2%) than did the uterus (41.8 +/- 2.3%; p = 0.0003). They also showed a more rapid increase in volume after cessation of therapy (p = 0.03). The control group showed an insignificant increase in the size of the uterus and individual leiomyomas over the 6 months' monitoring. The differences observed in reduction of the volumes of the leiomyomas and the uterus during the state of hypoestrogenism induced by buserelin, as well as in their regrowth after cessation of treatment, can be explained by the greater number of estrogen receptors in leiomyoma tissue and a possible lower rate of conversion of estradiol into estrone.
24名患有平滑肌瘤的女性（平均年龄42.0±2.4岁）接受了促性腺激素释放激素（GnRH）激动剂（布舍瑞林）治疗，为期6个月。最初2个月每日经鼻给予1200微克的剂量，随后4个月每日给予900微克。在治疗前、治疗期间每2个月以及治疗停止后6个月内每2个月（共7次评估）通过超声检查测量子宫和各个平滑肌瘤的体积。一个由14名未治疗平滑肌瘤的女性组成的对照组，在6个月内每2个月接受一次超声扫描。除一名患者外，在治疗的前2个月后观察到子宫和平滑肌瘤的体积显著减小。平滑肌瘤体积的减小幅度（54.6±2.2%）大于子宫（41.8±2.3%；p = 0.0003）。它们在治疗停止后体积也有更快的增加（p = 0.03）。对照组在6个月的监测期间子宫和各个平滑肌瘤的大小有不显著的增加。在布舍瑞林诱导的低雌激素状态期间观察到的平滑肌瘤和子宫体积减小的差异，以及治疗停止后它们的再生长差异，可以通过平滑肌瘤组织中雌激素受体数量较多以及雌二醇转化为雌酮的可能较低速率来解释。
